AstraZeneca’s (AZN) Buy Rating Reiterated at Jefferies Financial Group

AstraZeneca (LON:AZN)‘s stock had its “buy” rating restated by analysts at Jefferies Financial Group in a report released on Tuesday, Digital Look reports. They currently have a £175 target price on the biopharmaceutical company’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 39.31% from the company’s previous close.

Other equities research analysts also recently issued research reports about the stock. Royal Bank Of Canada restated an “outperform” rating and issued a £145 price objective on shares of AstraZeneca in a research report on Tuesday, September 8th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and set a £117 target price on shares of AstraZeneca in a research report on Tuesday, September 29th. Berenberg Bank reissued a “buy” rating and set a £175 target price on shares of AstraZeneca in a research note on Wednesday, October 7th. Finally, Citigroup raised their price target on AstraZeneca from £175 to £178 and gave the company a “buy” rating in a report on Tuesday, July 28th. Six analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, AstraZeneca presently has a consensus rating of “Moderate Buy” and a consensus price target of £153.57.

AstraZeneca Stock Performance

Shares of LON:AZN traded up GBX 162 during midday trading on Tuesday, hitting £125.62. The stock had a trading volume of 58,094,418 shares, compared to its average volume of 28,508,271. The company has a market capitalization of £194.82 billion, a PE ratio of 18.81, a P/E/G ratio of 0.86 and a beta of 0.20. The stock has a 50 day moving average price of £121.01 and a two-hundred day moving average price of £131.12. The company has a current ratio of 0.89, a quick ratio of 0.59 and a debt-to-equity ratio of 64.10. AstraZeneca has a 1 year low of £114.04 and a 1 year high of £157.32.

Insider Buying and Selling

In other news, insider Michel Demare bought 2,500 shares of the business’s stock in a transaction that occurred on Monday, September 14th. The stock was purchased at an average price of £121.21 per share, with a total value of £303,025. Corporate insiders own 0.15% of the company’s stock.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.